You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 66 No. 1, January 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •eTable and eFigure
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (1)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Anxiety Disorders
 •Psychopharmacology
 •Public Health
 •Substance Abuse/ Alcoholism
 •Magnetic Resonance Imaging
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Distinct Effects of {Delta}9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing

Paolo Fusar-Poli, MD; José A. Crippa, MD, PhD; Sagnik Bhattacharyya, MD; Stefan J. Borgwardt, MD, PhD; Paul Allen, PhD; Rocio Martin-Santos, MD, PhD; Marc Seal, MD, PhD; Simon A. Surguladze, MD, PhD; Colin O’Carrol, PhD; Zerrin Atakan, MD, PhD; Antonio W. Zuardi, MD, PhD; Philip K. McGuire, MD, PhD

Arch Gen Psychiatry. 2009;66(1):95-105.

Context  Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown.

Objective  To investigate the effects of 2 main psychoactive constituents of Cannabis sativa ({Delta}9-tetrahydrocannabinol [{Delta}9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing.

Design  Subjects were studied on 3 separate occasions using an event-related functional magnetic resonance imaging paradigm while viewing faces that implicitly elicited different levels of anxiety. Each scanning session was preceded by the ingestion of either 10 mg of {Delta}9-THC, 600 mg of CBD, or a placebo in a double-blind, randomized, placebo-controlled design.

Participants  Fifteen healthy, English-native, right-handed men who had used cannabis 15 times or less in their life.

Main Outcome Measures  Regional brain activation (blood oxygenation level–dependent response), electrodermal activity (skin conductance response [SCR]), and objective and subjective ratings of anxiety.

Results  {Delta}9-Tetrahydrocannabinol increased anxiety, as well as levels of intoxication, sedation, and psychotic symptoms, whereas there was a trend for a reduction in anxiety following administration of CBD. The number of SCR fluctuations during the processing of intensely fearful faces increased following administration of {Delta}9-THC but decreased following administration of CBD. Cannabidiol attenuated the blood oxygenation level–dependent signal in the amygdala and the anterior and posterior cingulate cortex while subjects were processing intensely fearful faces, and its suppression of the amygdalar and anterior cingulate responses was correlated with the concurrent reduction in SCR fluctuations. {Delta}9-Tetrahydrocannabinol mainly modulated activation in frontal and parietal areas.

Conclusions  {Delta}9-Tetrahydrocannabinol and CBD had clearly distinct effects on the neural, electrodermal, and symptomatic response to fearful faces. The effects of CBD on activation in limbic and paralimbic regions may contribute to its ability to reduce autonomic arousal and subjective anxiety, whereas the anxiogenic effects of {Delta}9-THC may be related to effects in other brain regions.


Author Affiliations: Section of Neuroimaging (Drs Fusar-Poli, Crippa, Bhattacharyy, Borgwardt, Allen, Martin-Santos, Seal, O’Carrol, Atakan, and McGuire) and Cognitive Neuropsychiatry (Dr Surguladze), Division of Psychological Medicine, Institute of Psychiatry, King's College London, London, England; Department of Applied and Psychobehavioural Health Sciences, University of Pavia, Pavia, Italy (Dr Fusar-Poli); Department of Neurology, Psychiatry, and Medical Psychology, Faculty of Medicine of Ribeirão Preto, University of Sao Paulo, Sao Paulo, Brazil (Drs Crippa and Zuardi); Psychiatric Outpatient Department, University Hospital Basel, Basel, Switzerland (Dr Borgwardt); and Melbourne Neuropsychiatry Centre, The University of Melbourne, Melbourne, Australia (Dr Seal).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2009;66(1):9.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use
Gonzalez-Pinto et al.
Schizophr Bull 2009;0:sbp126v1-sbp126.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.